Cyclic Diagnostics' new CEO to Lead New Era in Fertility Hormone Analysis
Cyclic Diagnostics is excited to announce the appointment of Michael Hartnett as Chief Executive Officer. Michael brings a wealth of experience in the healthcare sector, with over 26 years of leadership expertise, transforming and scaling healthcare companies backed by private equity.
Michael’s appointment comes at a pivotal moment for Cyclic Diagnostics as the company launches its disruptive Cyclic ProDX system. This innovative solution empowers fertility clinics by allowing them to conduct on-site hormone analysis, drastically reducing test processing times. The Cyclic ProDX system enhances clinicians' ability to make quicker, more informed treatment decisions, streamlining fertility care and improving patient outcomes.
In his new role, Michael will leverage his extensive background in diagnostics leadership, commercial strategy, and organizational culture to accelerate the adoption of Cyclic ProDX across the fertility industry. Known for his visionary leadership and ability to deliver growth above market rates, Michael is well-positioned to drive the company’s mission of transforming fertility care.
"I'm excited to join the Cyclic Diagnostics team to bring much-needed improvements to hormone analysis in IVF," said Michael. "Cyclic ProDX is a game-changing solution that enables clinics to take full control of hormone testing, making a real difference in patient care. I’m looking forward to helping clinics unlock the full potential of this technology."
With a proven track record of scaling healthcare businesses and fostering organizational cultures that prioritize customer and employee loyalty, Michael’s leadership is expected to position Cyclic Diagnostics as a market leader in fertility hormone diagnostics.
Reach out to Michael using our contact form here.
